Covered recipient · General Payments record
NICOLE LAMANNA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$117,739.85
- Reported across 147 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,375.00 | 3 |
| Food and Beverage | $695.21 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $4,487.74 | 6 |
| BeiGene USA, Inc. | $3,342.09 | 6 |
| Acerta Pharma LLC | $220.30 | 4 |
| Adaptive Biotechnologies Corporation | $20.08 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $1,375.00 | 01/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103136591 | CMS |
| ABBVIE INC. | $23.52 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104131838 | CMS |
| ABBVIE INC. | $20.65 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104131840 | CMS |
| ABBVIE INC. | $55.71 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104131842 | CMS |
| ABBVIE INC. | $12.86 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104131844 | CMS |
| ABBVIE INC. | $3,000.00 | 12/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103136593 | CMS |
| Adaptive Biotechnologies Corporation | $20.08 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150262924 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.35 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110540577 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.76 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110538397 | CMS |
| AstraZeneca Pharmaceuticals LP | $135.00 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110539167 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.19 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110541047 | CMS |
| BeiGene USA, Inc. | $3,000.00 | 02/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120858531 | CMS |
| BeiGene USA, Inc. | $79.52 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858533 | CMS |
| BeiGene USA, Inc. | $89.75 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858537 | CMS |
| BeiGene USA, Inc. | $107.38 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858539 | CMS |
| BeiGene USA, Inc. | $51.25 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858535 | CMS |
| BeiGene USA, Inc. | $14.19 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858541 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.